Prostatype

A genetic test to determine how aggressive the prostate cancer is, to navigate relevant treatment options.

Prostatype

Overview

The Prostatype test was developed by Prostatype Genomics after more than 15 years of research and is offered by Cambridge Clinical Laboratories. It is a genomic test that assesses how aggressive prostate cancer is. It guides whether immediate treatment is needed or if active surveillance is appropriate.



How it Works

  • Analyzes three stem-cell mRNA biomarkers (F3, IGFBP3, VGLL3) from existing biopsy samples. No new biopsy required.

  • Combines biomarker data with PSA levels, Gleason score, tumour stage, and clinical information.

  • Generates a P-score, indicating 10-year risk of death from prostate cancer without treatment.


    • Accuracy

  • Outperforms traditional models (D’Amico and CAPRA) in predicting prostate cancer mortality.

  • Enables 35% of patients to be safely reclassified to active surveillance, while confirming treatment for 65%.

  • P-score has a high prognostic accuracy (AUC ~0.89) and strong correlation with 10-year cancer-specific mortality (hazard ratio ~1.6).


    • Benefits

  • Reduces overtreatment and undertreatment.

  • Supports better-informed treatment decisions.

  • Offers cost-efficient and scalable use through existing biopsy materials.


    • Eligibility

  • Suitable for newly diagnosed patients who need clarity on cancer aggressiveness.

  • Also available for patients under active surveillance. Requires a more recent biopsy sample.

  • Access via private specialist consultants. Some named consultants currently offering it:

    • Tim Dudderidge (Spire Southampton)

    • Jaimin Bhatt (Ross Hall Clinic, Glasgow)

    • Utsav Reddy (Spire Norwich)

  • NHS patients must access Prostatype through private consultation, either via their NHS consultant offering private services or arranged through Prostatype’s facilitators.

    • Get your Prostatype test

    Prostatype offers men with prostate cancer a clearer picture of how aggressive their disease is, helping avoid both overtreatment and undertreatment.